Log in

300434 Sichuan Goldstone Asia Pharmaceutical, Inc. SZSE · China

Sichuan Goldstone Asia Pharmaceutical (300434) news

Sichuan Goldstone Asia Pharmaceutical, Inc. is a public biotech or pharmaceutical company listed on SZSE under the ticker 300434, recorded under China. The directory classifies it as Diversified pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Sichuan Goldstone Asia Pharmaceutical news

We have not published a story on Sichuan Goldstone Asia Pharmaceutical yet. When there is news, it will appear here.

Questions about Sichuan Goldstone Asia Pharmaceutical

What is the ticker symbol of Sichuan Goldstone Asia Pharmaceutical?

Sichuan Goldstone Asia Pharmaceutical, Inc. trades under the ticker 300434 on SZSE.

Where is Sichuan Goldstone Asia Pharmaceutical listed?

Sichuan Goldstone Asia Pharmaceutical, Inc. is listed on SZSE.

Which country or territory is Sichuan Goldstone Asia Pharmaceutical listed under?

Our directory records Sichuan Goldstone Asia Pharmaceutical, Inc. under China.

What does Sichuan Goldstone Asia Pharmaceutical do?

Our directory classifies Sichuan Goldstone Asia Pharmaceutical, Inc. as: Diversified pharmaceuticals. This is a directory classification, not a description of the pipeline.

What is the ISIN of Sichuan Goldstone Asia Pharmaceutical?

The ISIN recorded for Sichuan Goldstone Asia Pharmaceutical, Inc. is CNE100001YX5.

Does aibio.space cover Sichuan Goldstone Asia Pharmaceutical?

aibio.space lists Sichuan Goldstone Asia Pharmaceutical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Sichuan Goldstone Asia Pharmaceutical?

Companies in our directory listed in the same country and business area as Sichuan Goldstone Asia Pharmaceutical: CSPC Innovation Pharmaceutical Co., Huapont Life Sciences Co., Lushang Freda Pharmaceutical Co., Changzhou Qianhong Bio-Pharma Co., Laekna, Walvax Biotechnology Co..

Investor discussion: Sichuan Goldstone Asia Pharmaceutical

Members talk about Sichuan Goldstone Asia Pharmaceutical (300434). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open SZSE:300434 on TradingView.

Listing details

Sichuan Goldstone Asia Pharmaceutical, Inc. is a public biotech or pharmaceutical company listed on SZSE under the ticker 300434, recorded under China. The directory classifies it as Diversified pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Sichuan Goldstone Asia Pharmaceutical, Inc.
Ticker
300434
Listing
SZSE
Country or territory
China
Business scope
Diversified pharmaceuticals
ISIN
CNE100001YX5
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.